Advanced Glycation End-Products and Metabolomics Are Independently Associated With Frailty: The Longitudinal Doetinchem Cohort Study
The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences · 2025
DOI: 10.1093/gerona/glae272 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2025. Verfasst von Lieke M Kuiper und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Prevention, Lifestyle and Health, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands. Hauptthemen laut MEDLINE: Frailty, Glycation End Products, Advanced, Metabolomics, Skin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Netherlands Organization for Health Research and Development, Ministry of Health, Welfare and Sport of the Netherlands, National Institute for Public Health and the Environment.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Skin autofluorescence (SAF), reflecting advanced glycation endproducts’ accumulation in tissue, has been proposed as a noninvasive aging biomarker. Yet, SAF has not been compared with well-established blood-based aging biomarkers such as MetaboHealth in association with frailty. Furthermore, no previous study determined the longitudinal association of SAF with frailty. We used 2 382 Doetinchem Cohort Study participants’ (aged 46.0–85.4) cross-sectional data, of whom 1 654 had longitudinal SAF measurements. SAF was measured using the AGE Reader. MetaboHealth was calculated on 1H-NMR-metabolomics. Linear regressions were used for the associations of SAF and MetaboHealth on the 36-deficit frailty index and logistic regressions for being pre-frail or frail as determined by the frailty phenotype. Longitudinal associations were determined by an interaction term between age and SAF in a linear mixed model. SAF and MetaboHealth were associated with higher odds of pre-frailty (odd ratios per standard deviation SAF: 1.21 [1.10–1.32], MetaboHealth: 1.35 [1.24–1.49]) and frailty (SAF: 1.70 [1.41–2.06], MetaboHealth: 1.90 [1.57–2.32]). When mutually adjusted, both aging biomarkers remained associated with pre-frailty (SAF: 1.16 [1.05–1.27], MetaboHealth 1.33 [1.21–1.46]) and frailty (SAF: 1.52 [1.25–1.85], MetaboHealth: 1.75 [1.43–2.14]). Additionally, SAF and MetaboHealth were associated with higher frailty index scores (percentage increase per standard deviation SAF: 1.35 [1.00–1.70], MetaboHealth: 1.87 [1.54–2.20]), also after mutual adjustment (SAF: 1.02 [0.68–1.37], MetaboHealth: 1.69 [1.35–2.02]). SAF was also longitudinally associated with the frailty index (percentage per unit/year increase: 0.12 [0.07–0.16]). The mutual independence of SAF and MetaboHealth implies they capture distinct aspects of the aging process. Altogether, these findings emphasize SAF’s clinical potential as an age-related decline biomarker, which could be further enhanced when combined with MetaboHealth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Prevention, Lifestyle and Health, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
- Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Center for Health Protection, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
ORCID-Profile: Lieke M Kuiper
Förderung
- Netherlands Organization for Health Research and Development
- Ministry of Health, Welfare and Sport of the Netherlands
- National Institute for Public Health and the Environment
Zitieren
APA
Kuiper, L. M., Picavet, H. S. J., Rietman, M. L., Dollé, M. E. T., & Verschuren, W. M. M. (2025). Advanced Glycation End-Products and Metabolomics Are Independently Associated With Frailty: The Longitudinal Doetinchem Cohort Study. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences. https://doi.org/10.1093/gerona/glae272
Vancouver
Kuiper LM, Picavet HSJ, Rietman ML, Dollé MET, Verschuren WMM. Advanced Glycation End-Products and Metabolomics Are Independently Associated With Frailty: The Longitudinal Doetinchem Cohort Study. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences. 2025. doi:10.1093/gerona/glae272
BibTeX
@article{Kuiper2025,
author = {Kuiper, Lieke M and Picavet, H Susan J and Rietman, M Liset and Dollé, Martijn E T and Verschuren, W M Monique},
title = {Advanced Glycation End-Products and Metabolomics Are Independently Associated With Frailty: The Longitudinal Doetinchem Cohort Study},
journal = {The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences},
year = {2025},
doi = {10.1093/gerona/glae272}
}
EUVIMED